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Brian C. Betts,1 Jo-Anne H. Young,1,2 Celalettin Ustun,1,3 Qing Cao,3 Daniel J. Weisdorf1,3Human herpesvirus 6 (HHV6) may be an important pathogen following allogeneic hematopoietic cell trans-
plantation (HCT). We prospectively evaluated weekly HHV6 viremia testing after allogeneic HCT using
a quantitative polymerase chain reaction (PCR)-based assay. HHV-6 viremia was detected in 46 of 82
(56%) patients at a median of 23 days post-HCT (range: day 110 to 1168). More males (65% vs females
39%, P 5 .03) and recipients of umbilical cord blood (UCB 69% vs unrelated donor [URD], 46% vs sibling
donor [20%] grafts, P 5 0.01) reactivated HHV-6. Patients with HHV6 viremia had more cytomegalovirus
(CMV) reactivation (26% vs 5.5%, P5.01) and unexplained fever and rash (23.9% vs 2.7%, P5.01) compared
with patients without HHV6 viremia. High-level HHV6 ($25,000 copies/mL) versus lower levels were asso-
ciated with more culture-negative pneumonitis (72.7% vs 22.8%, P 5 .01). Twenty HHV6-positive patients
were treated with foscarnet, ganciclovir, or cidofovir for HHV6 or other coexistent viruses. Within 2 weeks,
HHV6 viremia resolved more commonly in treated (65%) than untreated patients (31%), P5 .02. Survival at
3 months was similar in treated and untreated patients (90% vs 81%, P5 .4). Survival at 3 and 6 months post-
HCTwere not affected by HHV6 positivity (3 months HHV61 85% vs 78%, P5.46; 6 months HHV61 70% vs
72%, P 5 .89) or by HHV6 level (3-month high level 73% vs 89%, P 5 .23; 6-month high level 64% vs 71%,
P 5 .54). Neither the occurrence of HHV6, degree of viremia, nor use of antiviral drugs influenced
short-term survival after HCT.
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Human herpesvirus 6 (HHV6), a member of the
Roseolovirus genus of the b-herpesvirus subfamily,
establishes primary infection as exanthem subitum in
the normal pediatric population [1,2]. With time, it
establishes latency in CD341 cells, monocytes, and
macrophages, similar to cytomegalovirus (CMV).
Over the last decade, HHV6 has been increasingly
recognized as an opportunistic and potentially life-
threatening pathogen after hematopoietic cell trans-
plantation (HCT) [3-13]. Following HCT, HHV6
infections are caused by reactivation of the virus
from latency [5,6]. HHV6 reactivation is detected in
the blood of 40% to 60% of patients after HCT,
most often by use of quantitative DNA polymeraseDepartment ofMedicine; 2Division of Infectious Disease;
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[4,7-9,12,14].
HHV6 viremia has been reported in association with
varyingorgandysfunction and clinical syndromes includ-
ing: delayed/impaired platelet recovery [10,12,13,15],
myelosuppression [4,8], encephalitis [5,8,10-12,16-23],
fever [4,14,24,25], rash [8,24-28], hepatitis [14],
pneumonitis [8,25,29-31], gastroduodenitis [8], CMV
reactivation, and graft-versus-host disease (GVHD)
[20,28,32-34].
Treatment indications are uncertain in patients
with HHV6 viremia following HCT [35]. HHV6
encephalitis is potentially fatal, and is a common indi-
cation for treatment [17,35]. Only 1 trial evaluated
preemptive treatment of HHV6 based on a positive
PCR test [16]. The development of reliable clinical
guidelines for the management of HHV6 viremia in
HCT recipients has historically been limited by the
lack of specificity of viremia testing, lack of specific
HHV6 clinical syndromes, and confounded by the
occurrence of asymptomatic viremia, which often
resolves without intervention.
In a prospective observational surveillance study,
we evaluated the demographic and clinical factors
associated with HHV6 infection and describe the
outcome of patients with HHV6 viremia following
antiviral treatment.
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Eighty-two patients who received an allogeneic
HCT at the University of Minnesota between Decem-
ber 1, 2005, and September 30, 2006, had serial DNA
PCR testing for HHV6. Patients received condition-
ing for transplant and prophylaxis of GVHD per active
institutional protocols. All transplant protocols and
written consent formswere approved by theUniversity
of Minnesota institutional review board, which also
approved this specific analysis.
Myeloablative (MA) conditioning regimens in-
cluded cyclophosphamide 60 mg/kg intravenous (i.v.)
daily for 2 days and 1320 cGy of total body irradiation
(TBI) given in 8 fractions. For double umbilical cord
blood (UCB) HCT, fludarabine 75 mg/m2 was added.
In reduced-intensity conditioning (RIC) regimens, flu-
darabine (40 mg/m2 i.v. daily for 5 days) was used with
TBI (200 cGy) with cyclophosphamide 50 mg/kg i.v.
for 1 day. GVHD prophylaxis included cyclosporine
(fromday23 to at least day1100) givenwith eithermy-
cophenolatemofetil (fromday23 today130) (n5 128)
or short-course methotrexate. High dose steroids were
administered for treatment of acute GVHD (aGVHD).
HHV6 viremia testing for all allogeneic HCT re-
cipients was to be performed weekly for 4 weeks start-
ing on day 114. Incomplete testing was primarily
because of patients’ discharge to the outpatient setting.
A median of 4 testings were performed per patient in
the 82 patients studied (range: 1-21). This testing in-
volved a quantitative PCR-based evaluation of
HHV6 DNA copies/mL whole blood in a certified
clinical virology laboratory (Focus Diagnostics,
Cypress, CA). The lower limit of detection for the as-
say was 500 copies/mL. Of the 82 patients screened, 14
had only 1 test performed. Of those 14 patients, only 2
individuals had a single positive value. Because the
tests were performed 1 week apart, only 1 high-
positive test was enough to reach the treatment thresh-
old. Although we considered viremia .25,000 copies
of HHV6 DNA as a clinically relevant cut point, we
also specifically reviewed any positive HHV6 PCR to
better understand the natural history of this virus in
HCT patients.
HHV6 disease was defined as viremia withHHV6-
compatible clinical syndromes (eg, engraftment delay,
hepatitis, pneumonitis, rash, or encephalitis). HHV6
hepatitis was defined as viremia plus any aminotrans-
ferase enzyme elevation on 2 different days, or elevated
bilirubin on 2 occasions, within a 1-week interval,
without evidence of GVHD or alternate explanation
for hepatitis. Liver biopsies were not performed on
any patients in this study. If there was another reason-
able explanation for liver function test (LFT) changes,
then they were not attributed to HHV6. HHV6 pneu-
monitis was defined as viremia and evidence of unex-
plained cough, hypoxia, or chest radiographicchanges with negative sputum or bronchial lavage cul-
tures and microbiologic or virologic studies. Pneumo-
nitis or pneumonia was not attributed to HHV6
viremia if a bronchoscopy or sputum culture identified
an alternate microbial etiology. Fever because of
HHV6 was defined as HHV6 viremia with otherwise
unexplained fever, most often with a macular erythem-
atous rash and without evidence of GVHD. HHV6
central nervous system (CNS) dysfunction and/or
encephalitis were defined as mental status changes,
headache, seizure/clonus, paresthesias, or compatible
changes on radiologic imaging accompanying viremia
or HHV6 detection in spinal fluid. Bone marrow
suppression was defined as recovery of HHV6 from
marrow aspirates by PCR, accompanying worsening
leukopenia, thrombocytopenia, and a hypoplastic
marrow.
CMV viremia testing using a quantitative CMV
DNA PCR assay (Abbott Molecular, Chicago, IL)
was performed weekly after day 114. Patients with
a CMV-seronegative donor and CMV-seronegative
recipient status were tested until day 160;
CMV-seropositive recipients or those with positive
donors were tested until day1100. Selected patients
continued CMV testing after day 1100, including
patients at high risk for late CMV disease (patients
treated with steroids for GVHD) or those who had
received treatment for CMV before day 1100.
CMV-seropositive recipients or those with sero-
positive donors received high-dose acyclovir prophy-
laxis (500 mg/m2 [10-12 mg/kg] i.v. every 8 hours
or 800 mg [18 mg/kg pediatric] orally 5 times
daily) until day 1100 following transplantation.
CMV-seronegative patients with a CMV-negative
donor who were seropositive for herpes simplex virus
received low (half the above) dose acyclovir prophylaxis
daily until day 160. All blood products were leukore-
duced by filtration, but untested for CMV status.
HHV6 viremia patients were treated according to
suggested institutional guidelines, though without
a formal, protocol-based therapy. Eight were treated
based on the levels of HHV6 viremia and associated
clinical complications. Other HHV6 positive patients
received ganciclovir, foscarnet, or cidofovir for other
contemporaneous viral infections. Because these drugs
were active against HHV6, these patients were in-
cluded in the treated HHV6 group totaling 20 patients
treated for HHV6. High-level HHV6 viremia was
defined as $25,000 copies/mL.
When antiviral therapy was required during neu-
tropenia, foscarnet was administered at 180 mg/kg/
day in divided dosing (renally adjusted as needed) for
induction 3 days, then continued as maintenance
(90 mg/kg/day in divided dosing) to complete 2 weeks
of therapy. HHV6 viremia was retested at 2 and 4
weeks after discontinuation of therapy. Acyclovir
prophylaxis was held during foscarnet treatment.
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ganciclovir, for predefined 8-week courses (2 weeks in-
duction, 6weeksmaintenance). In ganciclovir-resistant
or neutropenic patients, foscarnet (or cidofivir) was
administered for treatment of CMV [36].Statistical Analysis
Data on transplant patient characteristics, post-
transplantation complications, and outcomes were
prospectively collected by the Biostatistical Support
Group at the University of Minnesota using standard-
ized collection procedures. Patients and transplant
characteristics in each cohort were compared using
chi-square or Fisher exact test for categorical data
and Wilcoxon’s rank sum test for continuous data.
All patients were followed up until death or last
follow-up. Kaplan-Meier analysis was used to estimate
overall survival (OS) [37], and OS comparisons be-
tween different groups were completed by using
a log-rank test. All statistical analyses were performed
with Statistical Analysis System statistical software
version 9.2 (SAS Institute, Inc., Cary, NC) with
P-value #.05 considered to be statistically significant.RESULTS
Patients and HHV6-Associated Syndromes
The median age of patients was 26 years (range: 1-
66); 66% were males (Table 1). The incidence of
HHV6 viremia among the screened patients was
56% (46/82), with high-level HHV6 viremia
($25,000 copies/mL) in 13% (11/82) (Table 1). The
median time to viremia was 23 days post-HCT (range:
10-168) (Figure 1). Only 1 patient developed (low-Table 1. Human Herpesvirus 6 (HHV6) Infection following HCT
Characteristic HHV6 Viremia P* 5
No. of 82 tested 46 (56%)
Age
Median (range) years 24 (1-67) .86
<18 17/31 (55%)
$18 29/51 (57%)
Gender .03
Male 35/54 (65%)
Female 11/28 (39%)
Conditioning regimen .63
Reduced intensity 19/32 (59%)
Myeloablative 27/50 (54%)
Donor <.01
Sibling 3/15 (20%)
URD 6/13 (46%)
UCB 37/54 (69%)
CMV .25
+ recipient 25/40 (63%)
2 recipient 21/42 (50%)
CMV indicates cytomegalovirus; URD, unrelated donor; UCB, umbilical cord
*P-values reflect comparisons between HHV6-positive and HHV6-negative co
†P-values reflect comparisons between cohorts with low versus high level of Hlevel) HHV6 viremia before engraftment. The
majority of positive values, regardless of viral load,
occurred just after engraftment at the day 121 time
point. No difference in marrow suppression was ob-
served in any group surveyed. The rate of reduction
in HHV6 viral load was similar among all patients
treated, occurring very early in the course of therapy.
HHV6 viremia occurred more commonly in males
(65% vs 39% females, P 5 .03). Viremia developed
in 69%, 46%, and 20% patients receiving UCB, unre-
lated donor (URD), and sibling donor grafts, respec-
tively (P 5 .01). Conditioning regimen intensity,
donor-recipient gender and gender match, age, and
CMV-seropositivity in recipients did not affect the
incidence of HHV6 viremia (Table 1). There were
trends suggested that high-level (.25,000 copies/
mL) HHV6 viremia was somewhat more frequent in
males and younger patients (Table 1), but these find-
ings must be interpreted cautiously in the modest-
sized study cohort. UCB recipients did not have
more frequent high-level viremia.
All of the patients treated for any level of HHV6
viremia had actual HHV6 disease (viremia 1
syndrome), that is, no patients were treated for an ab-
normal PCR in isolation. In fact, all patients had at
least 3 symptoms compatible with HHV6 disease.
The majority of patients treated for HHV6 with
low-level viremia had CMV reactivation, LFT abnor-
malities, and marrow suppression at the time of
therapy. Patients treated for HHV6 associated with
high-level viremia had culture-negative pneumonitis,
LFT abnormalities, and marrow suppression.
Patients who developed HHV6 viremia had more
CMV reactivation (26% vs 5.5%, P 5 .01) and unex-
plained fever/rash (24% vs 3%, P 5 .01) compared
to nonviremic patients (Table 2). Lower levelHigh-Level Viremia ($25,000 Copies/mL) P† 5
11 (13%)
12 (1-66) .06
7/31 (23%)
4/51 (8%)
.06
10/54 (19%)
1/28 (4%)
.85
4/32 (13%)
7/50 (14%)
.54
0
2/13 (15%)
9/54 (17%)
.29
7/40 (18%)
4/42 (10%)
blood.
ntrols.
HV6 viremia.
Figure 1. The median time to viremia was 23 days.
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frequent CMV reactivation (28% vs 18%; P 5 .49)
(Table 2). CMV disease, rather than CMV reactiva-
tion, only occurred in 4 patients. These 4 patients
had concurrent HHV6 viremia as well. For this small
group of patients, the duration of foscarnet was ex-
tended because of the CMV. Of note, the reduction
inHHV6 viral load was similar in both groups, occur-
ring very early in the course of therapy. The remain-
ing 8 patients received either ganciclovir or cidofovir
at the discretion of the clinician.
HHV6 viremic patients experienced more rash/
fever (24% vs 3%, P 5 .01) (Table 2), but the inci-
dence of rash/fever was similar in low (23%) or
high-level viremia (27%, P 5 .76). The rates of
hepatitis, bone marrow suppression, CNS dysfunc-
tion, moderate-severe and aGVHD were similar in
the HHV6 viremia positive and negative patients
(Table 2). HHV6 syndromes occurred 89%, 100%,
and 100% of the patients with HHV6 viremia after
UCB, URD, and sibling transplantation, respectively
(P 5 .3). Culture-negative pneumonitis was slightly
more frequent in those with high- versus low-level
HHV6 viremia (72% vs 22%, P\ .01, vs nonviremic
patients, 19%). Patients with high versus low levels ofTable 2. Clinical Complications in Patients With or Without HHV
No Viremia HHV6 Viremia
N 36 46
Hepatitis 18 (50%) 18 (39%)
Pneumonitis 7 (19%) 16 (35%)
Fever/rash 1 (3%) 11 (24%)
CNS dysfunction* 10 (28%) 8 (17%)
CMV reactivation† 2 (6%) 12 (26%)
Bone marrow suppression/delayed engraftment 4 (11%) 7 (15%)
Acute GVHD grade II-IV 7 (19%) 16 (35%)
GVHD indicates graft-versus-host disease; CNS, central nervous system; CM
Shown is the crude incidence of the stated complications in cohorts with or w
*CNS dysfunction included: HHV62 patients, mental status changes 3, head
low-level patients, mental status changes 4 and headaches 2; HHV6 high-level
†CMV disease occurred in 4 patients, all of whom had concurrent HHV6 vireHHV6 viremia more often had 2 or more of the listed
complications (45% vs 9%, P 5 .02). Although the
incidence of CNS dysfunction was similar among
the patients with or without HHV6 reactivation,
mental status changes occurred more frequently in
patients with any level HHV6 viremia (Table 2, no
viremia N 5 3, HHV6 viremia N 5 6). Four patients
with a viral load \25,000 copies/mL developed
mental status changes. All patients in the low-level
viremia group with mental status changes survived,
with 1 patient receiving foscarnet (viral load of
21,000 copies/mL). Two patients with high-level
viremia, 27,000 and 38,000 copies, respectively,
developed mental status changes requiring foscarnet
therapy. The patient with 38,000 copies/mL of
HHV6 DNA died despite receiving foscarnet.
HHV6 PCR was assessed in the cerebral spinal fluid
for 1 patient and was undetectable.Antiviral Treatment
Of the 46 patients with HHV6 viremia, 20 (43%)
received antiviral treatment. Antiviral therapy in-
cluded ganciclovir (n5 11), foscarnet (n5 8), or cido-
fovir (n 5 1). HHV6 viremia became undetectable in
13 (65%) of the treated and in 8 (31%) of the un-
treated 26 patients, P5 .02. The median time to clear-
ance of the virus was 2 weeks in treated and 1.5 weeks
in untreated patients. HHV6 viremia recurred in 6
patients (5 treated and 1 untreated); 5 initially had
high-level viremia.
Therapy was given for viremia .25,000 copies of
HHV6 DNA. For patients with viremia under
25,000 copies, the administration of antiviral therapy
was at the discretion of the attending physician and in-
fectious disease consultants who were following the
patient, based on the overall clinical picture and pres-
ence of HHV6-compatible symptoms. Among the pa-
tients treated for HHV6 viremia \25,000 copies
of DNA, the average PCR value was 6500 copies of
HHV6 DNA, with a range of 300-21,000 copies.
The average peak day of HHV6 reactivation was day6 Viremia
P Low-Level (<25,000) High-Level HHV6 ($25,000/mL) P
35 11
.33 13 (37%) 5 (45%) .62
.12 8 (23%) 8 (73%) <.01
.01 8 (23%) 3 (27%) .76
.26 6 (17%) 2 (18%) .94
.01 10 (29%) 2 (18%) .49
.59 6 (17%) 1 (9%) .52
.12 13 (37%) 3 (27%) .55
V, cytomegalovirus.
ithout HHV6 viremia; or high- versus low-level viremia.
aches 3, seizures 1, paresthesias 1, clonus 1, cerebral edema 1; HHV6
patients, mental status changes 2.
mia.
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primarily included culture negative pneumonitis,
transaminitis/hepatitis, and slow engraftment.
The constellation of HHV6-specific symptoms
were similar for patients developing high-grade
viremia (ie, PCR measuring 25,000 copies of HHV6
DNA or greater). The average peak day of viremia
was within the first 2 to 3 weeks posttransplantation.
The average duration of persistent viremia of any
level, after reaching the threshold of 25,000 copies/
mL, was 20 days. Overall, 9 of the 11 patients experi-
enced a decrease in the HHV6 viral load, below the
threshold of 25,000 copies, within 1 week of initial
testing. Two of these patients did not receive any
active therapy forHHV6, whereas the others received
foscarnet or ganciclovir. Two patients developed
persistent high-grade viremia, with viral loads re-
maining above 25,000 copies/mL for 9 and 45 days,
respectively. The latter patient received ganciclovir
and survived.
Recurrent low-level HHV6 viremia occurredmore
frequently in patients who had previously developed
a high initial viremia. We observed that in the post-
transplantation setting, 45% of patients with high
primary viral loads and only 2% of patients with low
primary viral loads experienced a secondary viremia.
None of the episodes of recurrent HHV6 viremia
reached the 25,000 copies/mL threshold. Interest-
ingly, the majority of patients with recurrent HHV6
viremia received foscarnet during the primary infec-
tion, with the exception of the 1 patient with a low-
level primary viremia. The average interval between
the 2 episodes of posttransplantation HHV6 viremia
was 40 days, although the patient with the initial
low-level viremia recurred several months after the
primary infection. One patient with recurrent viremia
died of HHV6 infection, with significant CNS dys-
function and marrow suppression persisting from the
time of the initial high-level viremia.Survival
Forty (49%) of the 82 patients died at a median of
4.5 months (range: 0.7-26.0 months) following HCT.
OS was similar for HHV61 and HHV62 patients at
3 (85% vs 78%, P 5 .46), 6 (70% vs 72%, P 5 .89),
12 (63% vs 56%, P 5 .52), and 24 months (52% vs
53%, P 5 .93) post-HCT. OS was not influenced by
the level of viremia at 3 months (high- vs low-level
viremia, 73% vs 89%, P 5 .23), 6 months (64% vs
71%, P 5 .54), 12 months (64% vs 63%, P 5 .88),
and 24 months (55% vs 51%, P 5 .98).Antiviral Treatment and Survival
Among the 46 patients with HHV6 viremia,
survival was similar at 3 months in the treated andthe untreated patients (90% vs 81%, P 5 .4); a trend
toward improved OS at 6 months (85% vs 58%,
P 5 0.06), but no difference at 1 year (54% vs 75%,
P 5 .14) and 2 years (60% vs 46%, P 5 .29).DISCUSSION
This prospective observational study revealed that
HHV6 reactivation was common (56%) after alloge-
neic HCT, similar to earlier series reporting
a 40% to 60% HHV6 incidence [4,7-9,12]. Viremia
occurred early, most often within the first month
[5,7,9-11,29,34,38]. Some reports suggest that HHV6
reactivation occurs close to neutrophil engraftment
[10], but even with our larger number of UCB graft
recipients who often have slower neutrophil recovery
and presumably no adoptive anti-HHV6 immunity,
we cannot distinguish differences in the time of onset
or evolution of any HHV6 syndrome. The rate of
reduction in HHV6 viral load was similar among
all patients treated, occurring very early in the course
of therapy. By giving a short course of therapy early
after identification of new high-grade viremia, with
a rapid reduction in the viral load, we were able to
avoid giving excess treatment to some patients. All of
the cases of recurrent HHV6 viremia after foscarnet
therapy occurred with low viral loads, suggesting
that induction followed by a brief maintenance period
is adequate in this setting. The 1 death occurring
with low-level recurrent viremia was likely because of
persistent end-organ damage from the primary
infection.
Reported risk factors associated with HHV6
reactivation are uncertain, but include: younger age
[5], underlying disease [5], sex mismatch [5], HLA
mismatch [10,11], steroid treatment [5,10], URD
[10,11] or UCB grafts [11,15,25,28], and low pre-
HCT anti-HHV6 IgG levels [11]. We observed
more frequent HHV6 viremia in those receiving
UCB grafts and in males. HHV6 infection after
UCB transplantation is most likely from endogenous
viral reactivation rather than transmission through
the graft because HHV6 is rarely detected in
UCB [39-41]. Reactivation of CMV, another
b-Herpesvirinae family member, was common in
patients with HHV6 viremia [42,43]. However, we
observed a similar incidence of pretransplantation
CMV seropositivity in those with or without HHV6
viremia. The coincidentally recognized CMV
reactivation in the HHV6 viremic patients may
reflect impaired T cell immunity, a recognized risk
factor for reactivation of either virus [42,44-46].
However, in 2 previous independent analyses we
noted no increased risk of CMV reactivation in
recipients of UCB grafts [47,48]. Moreover, 1 recent
report suggested that HHV6, but not CMV
Biol Blood Marrow Transplant 17:1546-1568, 2011 1567HHV6 in HCTinfections, may be increased after UCB compared with
URD HCT [15]. Anti-HHV6 antibodies are uncom-
mon in UCB compared with adult donor grafts, but
the specific mechanisms associating HHV6 reactiva-
tion with UCB HCT remain uncertain.
HHV6 infection has been associated with several
clinical syndromes, but these associations are only
sometimes definitive with viral DNA isolated from
the affected tissues, most often marrow or CNS. In
the present analysis, mental status changes were the
manifestation of CNS dysfunction for 3 of 10 patients
with no viremia and for 6 of 8 patients with viremia.
(Headaches were the manifestation of CNS dysfunc-
tion for 2 of 6 patients with low viremia and for 0 of
2 patients with high-grade viremia.) Some of these syn-
dromes may be associated with a higher viral load as
well. We observed that HHV6 viremia occurred in
common with CMV reactivation and rash/fever, and
that high-level HHV6 patients had more culture-
negative pneumonitis.
Only a few studies evaluated treatment of HHV6
following allogeneic HCT [16,34,49]. Zerr et al. [49]
treated 11 patients with CNS dysfunction using gan-
ciclovir or foscarnet leading to decreased HHV6
levels in cerebrospinal fluid (CSF), but only 5 patients
survived. Ogata et al. [16] treated 6 patients with
a high level of HHV6 (.104 copies/mL) with
ganciclovir, yet resolution of viremia was neither
accelerated nor more common in the treated pa-
tients. However, a few patients had developed en-
cephalopathy before detectable plasma HHV6. We
observed clearance of HHV6 more commonly in
treated patients, but neither viral recurrence nor sur-
vival was influenced by antiviral therapy. Recurrence
of viremia developed in only 1 of 35 patients with low
HHV6 levels, but in 5 of 11 patients with initially
high levels.
There remains uncertainty about whether HHV6
viremia increases mortality [1,8,10,11,13]. Most
studies, as did ours, found no association between
mortality and HHV6 infection [8,10,11,13], likely
because of the frequent occurrence of spontaneously
resolving viremia and the complex, often
multifactorial interaction of immune deficiency,
GVHD, and coexisting complications in HCT
recipients who develop HHV6 viremia. The
pathogenetic association of HHV6 viremia and
related complications remains uncertain. Additional
prospective studies are required to determine
whether anti-HHV6 therapy (empirical or targeting
HHV6 disease) clears HHV6 and influences survival
for these patients.We suggest, however, that PCR sur-
veillance in higher-risk patients demonstrating other-
wise unexplained syndromes compatible with HHV6
is a rationale for therapy. Preemptive therapy in other-
wise asymptomatic viremic patients, regardless of de-
gree of viremia, may not be needed.ACKNOWLEDGMENTS
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